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A B S T R A C T
Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as
evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant re-
sidual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering
the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma
in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The
aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-
neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology
Working Group proposes a method for assessing TILs in these settings, based on the previously published
International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a
consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.
1. Introduction
Development and progression of malignant tumors are character-
ized by an interaction with the cells in the tumor microenvironment
including infiltrating immune cells. In the early stage HER2-positive
(HER2+) and in triple negative breast cancer (TNBC), immune in-
filtrates are detectable in up to 75% of tumors, with up to 20% of tu-
mors having a particularly dense infiltrate and with lower amount of
TILs in luminal subtypes [1].
Morphological evaluation of tumor-infiltrating lymphocytes (TILs)
in breast cancer (BC) is gaining momentum as evidence strengthens the
clinical relevance of this immunological biomarker, in particular in
HER2+ and TNBC subtypes. Accumulating evidence from several stu-
dies indicates that TIL density is predictive for response to neoadjuvant
chemotherapy (NACT) and, in certain BC subtypes, prognostic in pa-
tients treated with adjuvant chemotherapy. This suggests that treat-
ment response and outcome of BC varies with different TIL levels and
that the evaluation of TIL density in clinical trial cohorts –as well as in
daily histopathological practice- may prove to be of paramount re-
levance.
In this regard, high correlation of the immune gene expression with
TILs [2–4] further confirms that evaluation of TILs may be a valid, af-
fordable and readily available alternative. Furthermore, as archived
hematoxylin-and-eosin (H & E) slides can be evaluated for TILs, several
mature large datasets could be examined as to produce high quality
data required for level I evidence of TILs as prognostic/predictive
biomarkers.
NACT is being increasingly used in patients with primary TNBC or
HER2+ BC. The endpoint of pathological complete response (pCR) at
surgery is mostly considered as a surrogate of long-term survival and
suggests that the use of the neoadjuvant model may pave the way for
more efficient drug development. Nevertheless, recent studies suggest
that increased pCR rates do not necessarily translate into improved
outcomes. This implies that a more comprehensive analysis of the post-
NACT tumor is necessary. Two recent studies have also indicated that
higher TILs in post-NACT residual disease in TNBC are an important
independent predictor of improved survival [5,6]. However, in HER2+
disease, a single study suggests an adverse prognostic role of high TILs
in residual disease after NACT [49].
Similarly, TILs in ductal carcinoma in situ (DCIS), with and without
an associated invasive carcinoma, represent an emerging area of clin-
ical BC research since varying levels of TILs are encountered in DCIS.
Over the past few years, the International Immuno-Oncology
Biomarker Working Group on Breast Cancer (“The Working Group” in
the further text), with members including clinical research groups,
pathologists, clinicians and statisticians knowledgeable in BC, has de-
veloped standards for assessment of the immuno-oncology biomarkers
to aid pathologists, clinicians and researchers in their research and
daily practice. The group has licensed the first International Guidelines
on TIL Assessment in Breast Cancer [7] and in Solid Tumors [8].
In this report, a panel of pathologists, medical oncologists, biosta-
tisticians and translational researchers, with complementary expertise,
conducted a systematic review of the literature and propose a method
based on the International Guidelines on TIL Assessment in Breast
Cancer [7] which follows the methodology used in previous published
papers [5,9–11]. The methodology, while intended to remain as stan-
dardized as possible, was suggested, reviewed and discussed by mem-
bers of the Working Group, experts in their particular fields, to reach
the consensus opinion hereby presented.
The aim of this report is to update pathologists, clinicians and re-
searchers on TIL assessment in both the post-NACT residual disease
(RD) and the DCIS settings.
2. Tumor-infiltrating lymphocytes in the post-NACT residual
disease setting
NACT followed by surgery is nowadays considered the standard of
care for locally advanced/inflammatory BC and is increasingly used in
earlier stages with the aim to achieve a tumor down-staging and im-
prove the chance for breast conservation. In addition, it provides the
unique opportunity to test in vivo sensitivity to investigational agents,
potentially speeding up drug development. pCR, defined as the absence
of invasive residual carcinoma in the breast and axillary lymph nodes
after NACT, has been proposed as a surrogate endpoint for long-term
outcome [12,13]. However, rates and prognostic impact of pCR are
heterogeneous across different BC subtypes. The highly proliferative
and more aggressive subtypes such as non-luminal HER2+ BC and
TNBC have a higher chance to respond to NACT and the association
between failure to achieve pCR and unfavorable prognosis is mostly
evident in these subtypes, as compared to luminal BCs [13,14]. How-
ever, some patients without pCR will survive long-term, whereas some
patients with pCR will relapse, highlighting the limitations of pCR as a
surrogate endpoint for drug efficacy.
For these reasons, the identification of biomarkers to refine risk
stratification is urgently needed in order to enable a better identifica-
tion of high-risk patients eligible for additional systemic treatments.
TILs evaluated in RD after NACT have been suggested as a potentially
useful and reliable marker for this purpose. A first report by Asano and
colleagues suggests that the combination of the residual cancer burden
(RCB) and TILs is a significant predictor for breast cancer recurrence
after NACT and may be a more sensitive indicator than TILs alone [15].
The Working Group is launching an international effort to include TILs
in the RCB index in order to develop more accurate risk stratification
systems after NACT.
It may be argued that the evaluation of TILs on H & E-stained slides
does not capture the complexity of the tumor immune microenviron-
ment which is constantly populated by cells having pro-tumorigenic
and anti-tumor actions [16]. Therefore, some authors have focused on
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the immunohistochemical (IHC) characterization of TIL populations,
showing that the composition of TILs and the balance between the
immune effector and the pro-tumorigenic cells in RD was able to dis-
criminate patients at different risk of relapse [17,18]. However, the
basic morphological evaluation of TILs, on H& E-stained sections,
should still be considered the preferred method to be used in daily
practice. Being technically more feasible, it requires less biological
tissue and does not need additional processing on top of the pathology
routine. Moreover, in a large neoadjuvant study, predictive information
for response to NACT confirmed that TIL counts correlate well with the
immune gene expression [2], further emphasizing the strong biological
relevance of TILs when assessed using a standardized morphological
method. In addition, use of IHC requires additional processing as well
as further additional technical standardization. The global TIL count,
obtained on H& E, reflects well the net tumor immunogenicity and
classifies it in one of two clinically relevant categories: “hot”(inflamed,
TIL-rich) and “cold” (non-inflamed, TIL-poor)”. The H& E slides are
always available on existing trials, without block recollection required,
and therefore provide the quickest and easiest route to the body of
prospective-retrospective Level I–II evidence that needs to be obtained.
2.1. Available evidence
Available evidence on TILs in RD after NACT mainly focuses on
TNBC. RD after NACT predicts poor outcome [19]. At present, the
standard of care in the post-NACT setting for TNBC patients is ob-
servation [20]. Another option may be to consider the use of non-cross-
resistant chemotherapy such as capecitabine for 6–8 cycles, which has
been recently shown to reduce mortality in a single study, although 5-
year mortality remains above 20% [21].
Dieci and colleagues retrospectively evaluated TILs on H& E-stained
slides from surgical specimens of 278 TNBC patients with RD in the
breast after NACT. The authors reported a significant and independent
correlation between TILs, evaluated as a continuous variable, and both
metastasis-free and overall survival, with a 21% relative reduction of
the risk of metastasis and death for each 10% TIL increment. Patients
with high TILs (> 60% of stromal TILs) in post-NACT residual breast
tumors experienced significantly increased 5-year metastasis-free and
overall survival rates than the patients with lower TILs (81.5% vs 46%,
HR 0.24, 95% CI 0.09-0.64 for metastasis-free and 91% vs 55% HR
0.19, 95% CI 0.06–0.61 for overall survival). Interestingly, the prog-
nostic power of post-NACT TILs was greater in the group with a large
residual tumor burden (node positive and/or breast residual tumor with
diameter of more than 2 cm). More recently, Loi and colleagues eval-
uated TILs in a series of 111 TNBC with RD after NACT. Lymphocytic
infiltration in RD proved to be significantly and independently asso-
ciated with both relapse-free survival and overall survival, showing
consistency with the previous study. In addition, the authors reported
that the residual tumors with low TILs were enriched in activating
genomic alterations in the RAS-MAPK pathway (amplifications in
KRAS, BRAF, RAF1, and truncations in NF1) resulting in the suppression
of MHC-I/II expression. These results suggest that the activation of RAS-
MAPK pathway might represent one possible mechanism by which
tumor cells bypass the antigen presentation processes [6]. A recent
study has assessed the role of TILs in RD after NACT and trastuzumab
for HER2+ disease, suggesting an adverse prognostic role for high TIL
levels [49].
However, standardized, analytically validated methods for TIL as-
sessment are a prerequisite for the clinical utility of the results.
2.2. Methodological considerations for TIL assessment in the residual
disease setting
Formal recommendations for TIL assessment on H& E-stained slides
of primary untreated BC samples have been previously developed by
the Working Group. More recently, the Working Group has conducted a
RING which demonstrated that pathologists can be educated to score
TILs, herewith achieving high interpersonal concordance compared to
the non-trained pathologists (see below). This study definitively proves
that TILs can be assessed by pathologists in daily practice [7,22].
However, these recommendations may not be fully transposable to
the post-NACT samples, due to the well-recognized tissue-related pe-
culiarities of this particular post-treatment setting [23], further dis-
cussed below. One may argue against the need to assess TILs in the post-
NACT residual disease, since TILs assessed on pre-NACT core biopsies,
using the established guidelines, have been shown to predict prognosis
for patients treated with NACT [24,25]. It is now accepted that the
antitumor effect of chemotherapy is partially exerted through the
modulation of the immune system, in a process known as immunogenic
cell death [26,27]. TILs evaluated in the residual tumor after exposure
to chemotherapy could carry additional prognostic information, com-
pared to the baseline TILs, as they may partly reflect the reaction of the
immune microenvironment to chemotherapy. This has been supported
by the observation that the administration of chemotherapy results in
the attraction to and activation of TILs in the tumor bed [28]. Similarly,
the HER2+ BC patients showed an increase in TILs after exposure to
trastuzumab, even in case of short-term therapy, according to the pre-
sumed immune-mediated mechanism of action of monoclonal anti-
bodies [29–31]. Therefore, TILs in RD differ in nature not only from
baseline TILs but may also reflect the treatment ability to elicit an an-
titumor immune response. For that reason, focusing on pre-treatment
TILs may lead to missing of an important piece of clinical information.
This is corroborated by the emerging development of the clinical trials
for patients with residual disease after neoadjuvant therapy. Thus, the
need to determine a modified scoring method, specific for the post-
NACT BC specimens and based on simple and easy to adopt criteria,
becomes relevant.
2.3. TIL assessment in the post-NACT residual disease setting: ongoing
standardization efforts
2.3.1. The RING study
Considering the clinical need to develop a method of TIL assessment
in the post-NACT RD, in early 2016 the Working Group has started
standardization of TIL assessment in this setting. By mid-2016, a RING
study was launched to assess reproducibility of TIL assessment and to
highlight difficult areas that need to be discussed in order to optimize
the scoring methodology. A guide for TIL assessment in RD, developed
on the basis of the methods used in previous studies [2,3,5,9,10] and on
the established recommendations for TIL assessment in primary un-
treated BC [7], was circulated among six pathologists experienced in
TIL evaluation. Digitalized H& E slides from 50 cases with residual
TNBC were independently scored for stromal TILs by each pathologist.
Reproducibility was evaluated by intra-class correlation coefficient
(ICC), which showed a moderate concordance between pathologists for
stromal TIL evaluation (0.59, 95% CI 0.45–0.70). Further details on
methods and results can be found in Supplementary File 1.
This result should be regarded as encouraging since the study was
carried out by pathologists who had not received previous training on
TIL assessment in the post-NACT RD. A moderate inter-observer con-
cordance has been reported for many of the biomarkers routinely as-
sessed in BC samples, as histologic grade and Ki67, nonetheless not
restricting their widespread use in clinical practice and inclusion in
international guidelines. In addition, for Ki67, a global effort of stan-
dardization is ongoing [32].
However, to what extent the encountered variability in biomarker
assessment impacts prognosis, clinical outcome and, eventually, clinical
utility of a biomarker, remains largely unexplored for most of the
routinely used biomarkers in pathology. In order to explore the clinical
relevance of different degrees of inter-observer concordance in TIL as-
sessment, the Working Group conducted an in silico study focused on
the available pre-treatment TIL data from the neoadjuvant GeparSixto
M.V. Dieci et al. Seminars in Cancer Biology xxx (xxxx) xxx–xxx
3
trial [33], with pCR as the primary endpoint. Available TIL scores were
perturbed by a mathematical model simulating a situation in which the
complete dataset of the 580 samples of the GeparSixto study would be
evaluated by 4500 pathologists, in 9 groups of 500 each, with different
ICC for each group, obtaining a total of 2 610 000 values. The simu-
lation was based on the error model developed from published RING
studies on TIL assessment in primary untreated BC. In the original study
dataset, each 10% increase in baseline TILs was associated with a 20%
increase in pCR. The data were analyzed analogously for each group of
pathologists. For ICC coefficients from 0.6 to 0.9, 100% of pathologists
have odds ratios comparable to those of the original study. Even with
low ICCs of 0.4 and 0.5, most of the evaluations were still significant for
prediction of pCR (Supplementary File 2).
This study suggests that a degree of inter-observer variability may
not directly impact clinical outcome and might need to be detailed for
most of the biomarkers in order to allow the determination of the
clinically allowable error margin, meaning “what is the error margin
that is allowed among pathologists without this affecting clinical out-
come?” We nonetheless emphasize that pathologists need to score TILs
as accurate as they possibly can. This level of agreement is still high
enough to be useful in research studies on hundreds of patients, as the
net biology will show through the noise of the analytical variability at a
statistically significant level. Nevertheless, the same level of variability
is not acceptable for a single sample call leading to a clinical treatment-
oriented decision for a specific patient.
The RING study represented the springboard for the identification of
the main areas of uncertainties that were discussed at the San Antonio
Breast Cancer Symposium in 2016 (SABCS 2016), and that has led up to
the current recommendations.
2.3.2. Areas of uncertainties in TIL assessment in the post-NACT residual
disease setting
The aim of the next section is to discuss the areas of controversies in
the assessment of TILs in the post-NACT RD and to describe strengths
and weaknesses of various possible approaches, reflecting the discus-
sions held by the Working Group at the SABCS 2016 meeting.
Table 1 summarizes the recommendations developed for assessment
of TILs in primary BC when related to the RD after NACT. The main
aspects that challenge application of the available recommendations for
TIL assessment in the post-NACT RD are the different patterns of re-
sponse and tumor shrinkage that may be induced by NACT or other
types of treatment, and the wide range of possible post-treatment
changes that can be found in these samples [23]. The major topics of
uncertainty are: (i) selection of the tumor area to evaluate and (ii)
identification of relevant TILs to be included in the assessment.
According to the recommendations for primary untreated BC [7],
TIL assessment should be conducted on the area limited by the borders
of the primary invasive tumor. Despite the use of imaging, macroscopic
features, extensive sampling and microscopic assessment, the area
within the borders of primary untreated tumor in the post-NACT setting
is difficult – occasionally even impossible – to be delineated due to
tumor shrinkage.
There are, however, two different tissue areas usually assessable in
the post-NACT setting:
The first can be regarded as the “area of regression”; it can be
identified by radiological and gross pathology findings or stroma re-
actions, and by signs of regression at microscopic evaluation irrespec-
tive of the borders defined by the presence of tumor cells. The second
possibility is to focus on the “residual tumor bed”, defined as the largest
cross-sectional area between residual invasive cells, consistent with the
definition of Residual Cancer Burden (RCB) [34]. As discussed further
in the text, these two areas may overlap.
The second key step is to define where to evaluate TILs. The re-
commendations for untreated BC stress the relevance of TILs localized
in the tumor stroma of the selected area as the main parameter to be
considered [7]. Intra-epithelial tumor TILs can be included, for research
purposes, in the post-NACT setting, although assessment may prove
more difficult without additional tools like IHC. According to the
available recommendations, stromal TILs should be assessed by de-
termining the percentage of the tumor stroma surface of the selected
area that is occupied by mononuclear inflammatory cells. Areas that
should be excluded from the assessment include: necrosis, fibrosis,
stroma associated with in situ carcinoma or normal lobules, large fi-
brous areas, crush artefacts and areas of regressive hyalinization. These
major recommendations are applicable to the post-NACT setting,
bearing in mind that after treatment it is more likely to see fibrotic and
necrotic areas (sometimes replaced by aggregates of histiocytes and
cholesterol clefts), as well as regressive hyalinization. All those areas
should be excluded from the TIL assessment, except when the tumor
cells are within these aggregates of histiocytes and lymphocytes, com-
plicating in this particular setting the assessment of TILs. Moreover, one
of the NACT response pattern consists of residual scattered cell foci or
of isolated tumor cells, separated by large stromal areas [23]. TILs may
be found close to the tumor foci as well as dispersed in the stroma of the
selected area, far from residual invasive cells. A still unproven as-
sumption is that only TILs adjacent to the invasive tumor cells/foci have
Table 1
Recommendations for assessment of TILs in primary BC and their adaptation to RD after NACT.
TILs in primary untreated BC [18] TILs in RD
Selection of tumor
area
Within boundaries of the invasive tumor. Within the borders of the tumor area. How to define the tumor area of RD?
– Area of regression according to radiological/gross/microscopic findings
– Residual tumor bed defined as the largest cross-sectional area between residual
invasive tumor cells.
Include TILs at the invasive edge in the average assessment
Do not focus on hotspots Do not focus on hotspots
Do not include: DCIS, normal lobules, necrosis, large fibrous
areas, crush artefacts, regressive hyalinization
Do not include: DCIS, normal lobules, necrosis, large fibrous areas, crush artefacts,
regressive hyalinization. However, more challenges may be posed in the post-neoadjuvant
setting since alterations such as regressive hyalinization, necrosis (sometimes replaced by
aggregates of hystiocytes and cholesterol clefts), fibrous areas and stroma infiltrated by
sheets of foamy hemosiderin-loaded histiocytes are often found after NACT.
Type of immune cells All mononuclear cells, exclude polymorphonuclear
leukocytes.
All mononuclear cells, exclude polymorphonuclear leukocytes.
Localization Stromal TILs as the main parameter. Intratumoral TILs can be
included for research purposes.
Stromal TILs as the main parameter. Intratumoral TILs can be included for research
purposes.
StrTILs definition: % of stromal areas occupied by
mononuclear inflammatory cells.
StrTILs definition: % of stromal areas occupied by mononuclear inflammatory cells,
within the boundaries of the residual tumor bed as defined by the RCB-index.
Scoring method Continuous variable. Continuous variable.
Scan across tumor bed (50–100×) and then estimate average
TILs across microscopic fields (200–400×).
Scan across tumor bed (50–100×) and then estimate average TILs across microscopic
fields (200–400×).
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a relevant immunological function, as compared to TILs found dis-
persed far from the tumor cells [35]. This assumption raises the ques-
tion of whether to consider the entire stromal surface or the area
around scattered foci only.
As illustration, two examples showing the patterns of response to
NACT are provided in Figs. 1 and 2.
2.3.2.1. Concentric shrinkage, high cellularity (Fig. 1). In this case, the
response consists in concentric tumor shrinkage, with high cellularity
maintained.
As shown in Fig. 1A, the area of regression usually extends beyond
the residual tumor bed. Analyzing only the residual tumor bed area has
two advantages: i) it complies with the definition of the Residual Cancer
Burden [23,34] and ii) it is less affected by the micro- and macroscopic
modifications of the BC tissue after NACT, so its delineation is likely
more reproducible compared to the delineation of the regression area.
Furthermore, the use of a larger area as the denominator might some-
times lead to a reduced TIL score. In addition, the adoption of the
residual tumor bed area as the area for post-NACT TIL assessment
would be consistent with the assumption that TILs located near cancer
cells have a higher biological and clinical value. On the other hand, it
cannot be excluded that the assessment of TILs dispersed in the stroma
beyond the residual tumor area, but within the area of regression, might
capture potentially relevant information. More research is needed to
define the importance of spatial heterogeneity of tumor immune mi-
croenvironment in the post-neoadjuvant treatment setting.
It is worth noting that the area of regression does not necessarily
corresponds to or is identified within the extent of the primary un-
treated tumor but more often covers an intermediate surface between
the two extremes, the extension of the primary untreated tumor and the
residual tumor bed. Finally, in some cases of the concentric shrinkage
response pattern, the area of regression may overlap with the residual
tumor bed, with no signs of regression found beyond the area delimited
by invasive cells. In such condition, both approaches would identify the
same area for TILs evaluation (Fig. 1B).
2.3.2.2. Decrease in tumor cellularity, no concentric shrinkage (Fig. 2). In
this case, pattern of response consists of residual scattered foci of
carcinoma dispersed in a large stroma area.
The main controversy here is not the delineation of the area to be
assessed for TILs, since the area of regression and the residual tumor
bed may overlap (Fig. 2), but whether to consider the whole eligible
stromal surface (within the selected area) as the denominator for TIL
evaluation.
As already mentioned, TILs found immediately adjacent to the
tumor cells/nests may carry more biologically relevant information
than scattered TILs within the stroma far from the tumor foci [35].
However, definition of the extent of the area surrounding residual
tumor cells/nests to be included in TIL analysis may be challenging. In
addition, the amount of TILs surrounding residual scattered foci may be
heterogeneous, which is another limitation of this approach. Using the
average TIL score, determined on the whole eligible stromal surface,
including TILs at distance from tumor foci, may be one solution.
However, this does carry a risk of TIL score reduction.
The two paradigmatic patterns of response presented here represent
the two extremes of a wide spectrum of possible mixed responses [23].
Moreover, a much-debated issue is whether TIL evaluation can be
performed in case of pCR. Although challenging, the evaluation of the
immune infiltrate in pCR cases might be technically feasible. In this
condition, the sole definition of the area for TIL assessment that would
make sense is the area of regression. However, the main uncertainty is
the biological and clinical relevance of such analysis. To date, available
evidence is inadequate and we encourage clinical research groups to
score TILs even in pCR in order to acquire evidence.
Fig. 1. Concentric tumor shrinkage as response to NACT. Gray-sha-
dowed surface: area of regression; green line: residual tumor bed;
purple spots: mononuclear inflammatory cells. 1A: area of regression
extending beyond the residual tumor bed; 1B: area of regression
overlapping and confined to the residual tumor bed. (For interpreta-
tion of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 2. Reduced tumor cellularity as response to NACT, without concentric shrinkage.
Gray-shadowed surface: area of regression; green line: residual tumor bed; purple spots:
mononuclear inflammatory cells. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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2.3.3. Recommendations for a scoring method for TILs in the post-NACT
residual disease setting
Careful discussion of lessons learned from the initial concordance
study has led the members of the Working Group to propose a reference
method for TIL assessment after neoadjuvant treatment.
The proposed method is based on the methodology used in the
published studies [2,3,5,6,9,10], combined with adjustments derived
from the experience of the RING study. A summary of the guidance in
the form of a tutorial including pictures is available in Table 2 and as
Supplementary File 3.
We propose the residual tumor bed area as the area for TIL assess-
ment in the post-NACT setting, in concordance with the Residual
Cancer Burden definition [34] since this variable is widely used in daily
practice and clinical studies. Clear instructions on how to measure the
RCB are available and its prognostic significance has recently been
established [36]. The clinical utility of TILs as an immune biomarker in
RD may help discriminate poor or intermediate prognosis patients who
would be suitable for clinical trials of post-neoadjuvant systemic
treatments from the patients potentially cured by NACT. In this context,
adding the residual tumor TILs to other factors, such as RCB, may
further improve the performance of prognostic models. Indeed, RCB has
been validated as a strong prognostic parameter capable of overcoming
limitations of a simplistic dichotomization of response in pCR or non-
pCR [34,36]. In order to enable such integration of TIL scores into post-
NACT RD evaluation in breast cancer, the most coherent and pragmatic
approach is to adopt the criteria used for delimitation of the tumor bed
for the RCB index [34].
Related to the second main area of controversy, this referral method
proposes to include the whole stroma surface of the identified residual
tumor bed as the denominator for TIL assessment. This will avoid the
introduction of additional subjective elements to the scoring method
that would increase variability in interpretation, like the definition of
the extent of the area around scattered tumor foci. However, if those
scattered tumor foci are separated widely from each other, then the
area around each foci should be considered for TIL assessment and then
averaged in a similar manner as the TIL assessment in DCIS re-
commends.
Furthermore, several ongoing studies are scoring TILs in the
neoadjuvant setting on core biopsies taken after a short period of
treatment (targeted therapy or chemotherapy) but prior to surgery. The
current recommendations also apply to this setting. This means that
only cores with tumor should be assessed. Cores with scarred and in-
flammatory stroma but with no tumor cells should not be assessed. This
is in line with the current recommendations on assessing only TILs
surrounding tumor cells. Also, the rules proposed here for delineation of
residual tumor area of course do not apply to core biopsies since such
delineation is impossible on that type of tissue sample.
This scoring method is intended to provide guidance for the ongoing
or future studies assessing the clinical relevance of TILs in post-
neoadjuvant RD. It clearly does not claim to be perfect and fully ac-
knowledges its limitations. However, putting forward a simple tool for
TIL assessment would help homogenizing data from different studies
and facilitate interpretation of results in a consistent fashion. The
adoption of a unique scoring method in clinical research would,
through acquisition of comparable results, allow a faster increase in
scientific knowledge and the comprehension of the clinical utility of
TILs in RD, besides avoiding waste of efforts and resources, as the ex-
perience with Ki67 has shown.
3. TIL assessment in the ductal carcinoma in situ (DCIS) setting
3.1. Available evidence
There are only few studies which evaluated the prevalence and
prognostic relevance of TILs in DCIS. TILs are present in most DCIS at
varying levels (Fig. 3), however only a minority of DCIS show>50%
stromal TILs, which represented only 6.5% of cases in the largest study
[11]. The most frequent TILs are CD3+ cells (CD4+ being more fre-
quent than CD8 + ), followed by CD20+ cells and FOXP3+ T-reg-
ulatory cells (Tregs) [37]. High TILs in DCIS have consistently been
associated with adverse histopathologic features including high nuclear
grade, comedo necrosis, high Ki67, high VNPI (Van Nuys Prognostic
Index), as well as triple negative and HER2+ subtype [11,37,38].
Significantly higher levels of TILs have been found in cases of DCIS with
micro-invasion [37,39,40].
Research to date has not demonstrated an association between TILs
and recurrence risk in DCIS [11,39,40]. The largest study, which
evaluated 1488 cases of DCIS with a median follow-up of 8.2 years,
found no significant association between ipsilateral breast event and
Table 2
Recommendations for assessing tumor-infiltrating lymphocytes (TILs) in solid tumors in
the residual disease setting.
1. TIL-assessment in the residual disease setting should be done within the borders of
the residual tumor bed, as defined by the presence of the residual tumor cells, in
analogy with the definition of the residual tumor bed of the Residual Cancer
Burden (RCB)-index [21].
2. The entire largest cross-sectional area of the residual tumor bed should be used for
histologic TIL-assessment. One section (4–5 μm) per patient can be considered to
be sufficient for practical purposes.
3. However, if the residual tumor bed is large than 2 cm more slides need to be
assessed, with one slide for each cm of tumor bed as a minimum. For example, if
the largest diameter is> 5 cm, then at least 5 representative slides from the
largest cross-sectional area should be considered. If the residual tumor bed is thus
only 2 cm one slide is considered enough. Assessing numerous slides for each
case should thus be possible mentioning the number of assessed slides
specifically in the study protocol.
4. To assess TIL-cellularity it is helpful to scan across the sections of tumor bed
(50–100× magnification) and then estimate the average TIL-cellularity from the
different microscopic fields and slides (200–400× magnification).
5. Areas of tumor necrosis may be replaced by aggregates of histiocytes with
cholesterol clefts. TILs associated with these necrotic areas should be excluded.
6. Exclude TILs in tumor zones with crush artefacts
7. Exclude TILs closely related to remaining foci of carcinoma in situ or normal
lobules within the residual tumor bed.
8. TILs should be assessed when tumor cells are embedded within aggregates of
histiocytes.
9. TILs can be assessed on core biopsies after a short period of treatment (targeted or
chemotherapy), prior to surgery, only when they contain tumor cells. Cores with
scarred and inflammatory stroma but with no tumor cells should not be assessed.
10. TILs should be reported separately for the stromal compartment (% stromal TILs)
and the tumor cell compartment (% intra-epithelial tumoral TILs). The reasons
are that in many tumors the TIL density in the two compartments is different. The
denominator used to determine the% stromal TILs is the area of stromal tissue
(i.e. area occupied by mononuclear inflammatory cells over total stromal area),
not the number of stromal cells (i.e. fraction of total stromal nuclei that represent
mononuclear inflammatory cell nuclei in the stroma). Similarly, for intra-
epithelial tumoral TILs the tumor cell area is the denominator, not the stromal
area.
11. Do not focus on hotspots.
12. All mononuclear cells (including lymphocytes and plasma cells) should be scored,
but polymorphonuclear leukocytes are excluded.
13. TILs may provide more biological relevant information when scored as a
continuous variable, since this will allow more accurate statistical analyses,
which can later be categorized around different thresholds. However, in daily
practice most pathologists will rarely report for example 13.5% and will round
up to the nearest 5–10%, in this example thus 15%. Pathologist should report
their scores in as much detail as he/she feels comfortable with.
14. TILs should be assessed as a continuous parameter. The percentage of stromal or
intra-tumoral TILs is a semi-quantitative parameter for this assessment, for
example, 80% stromal TILs means that 80% of the stromal area shows a dense
mononuclear infiltrate. For assessment of percentage values, the dissociated
growth pattern of lymphocytes needs to be taken into account. Lymphocytes
typically do not form solid cellular aggregates, therefore the designation “100%
stromal TILs” would still allow some empty tissue space between the individual
lymphocytes.
15. Do not include: DCIS, normal lobules, necrosis, large fibrous areas, crush
artefacts, regressive hyalinization.
16. In case of complete pathological regression, TILs may, for specific research
purposes be assessed in the area of regression as defined by imaging, macroscopic
and microscopic features.
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TILs, using either continuous or categorical cut-points for TILs [11].
However, studies investigating the leukocyte subpopulations in DCIS
have found some associations with the recurrence risk. In a study by
Thompson et al. high numbers of FOXP3+ regulatory T-cells in DCIS
were associated with increased recurrence risk [37]. In one study,
which focused on 16 immune cell subpopulations in DCIS, high num-
bers of activated CD8 + HLADR + cytotoxic T-cells, low
CD8 + HLADR- T-cells and low CD115+ macrophages were associated
with low recurrence risk [38]. Knopfelmacher and colleagues found an
association between dense chronic inflammation around DCIS and high
Oncotype DCIS score [41].
Evidence of an active adaptive immune response in DCIS suggests
that immune-based strategies might be effective for treatment and
secondary breast cancer prevention. Expression of the immune check-
point ligand PD-L1 in 81% of TILs in DCIS cases, along with the sig-
nificant association of PD-L1 expression and high TILs, as demonstrated
in one study, suggests that PD-L1 blockade might be a valuable ap-
proach [37]. Further evidence supporting an active adaptive immune
response in DCIS is seen in the phenomenon known as “healing”.
“Healing” is a regressive change in DCIS resulting in prominent peri-
ductal fibrosis which often obliterates the DCIS. Healing in DCIS is
significantly associated with high TILs, particularly with CD8+TILs,
and likely to represent a lymphocyte-mediated response to DCIS [42].
Healing is noted predominately in HER2+ DCIS. Pruneri and collea-
gues also found highest TILs in the HER2+DCIS subtype suggesting
this is the most immunogenic DCIS [11]. Thus, although available
evidence so far, based on a retrospective series, suggest that total TILs
does not predict recurrence risk, preliminary studies support an active
adaptive immune response in DCIS which could be targeted by im-
mune-based therapies.
3.2. Methodological considerations of TIL assessment in ductal carcinoma
in situ
3.2.1. TIL assessment on H & E
Based on published evidence [11] and discussions within the
Working Group (SABCS 2016) on the methodology for TIL assessment
in this particular setting, we propose recommendations for harmonizing
TIL evaluation in carcinoma in situ of the breast (CIS). Although evi-
dence is currently limited to DCIS, these recommendations are also
applicable to TIL assessment in lobular carcinoma in situ. This method
has been found to be very reproducible across 4 pathologists in the
study of Pruneri et al. [11]. A reference scoring sheet and a tutorial are
included as Supplementary Files 4–5.
As in invasive breast cancer, TILs in breast CIS are first evaluated on
H& E-stained sections of formalin-fixed, paraffin-embedded tissues.
Three principal scenarios can be encountered: 1) pure CIS, 2) CIS with a
micro-invasive carcinoma [43] and 3) CIS with an invasive carcinoma.
The same methodology should be used in all situations, where the first
rule is not to evaluate TILs in the areas with invasion, whatever the size
of invasion is. The areas of microinvasion are frequently found very
close to the CIS areas, which can render their distinction difficult from
the in situ lesion. Data on TILs in microinvasive breast carcinomas are
still limited. Higher TIL density in the areas with micro-invasion has
been reported [40,44], however this is not encountered in all cases.
More studies are needed to better understand the role of TILs in the
microinvasive breast carcinoma, however, we recommend doc-
umenting TIL counts in this setting in order to acquire insights into the
global immunogenicity of the invasive cells. Similarly, we recommend
indicating how the amount/density of the TILs surrounding the micro-
invasive component compares to the rest of the lesion.
Current evidence supports the assessment of stromal (or“per-
iductal”) TILs in CIS of the breast. Stromal TILs in CIS are the TILs
located in the specialized breast stroma around ducts or acini filled with
CIS. As in invasive breast cancer [7], the% stromal TILs in breast CIS is
calculated as the% of the specialized stromal area surface occupied by
TILs. In cases where the specialized periductal stroma is not clearly
recognizable, the area considered as the specialized stroma in breast
CIS is defined, by some authors, as the area adjacent to the CIS islands
(the “periductal” area) which may extend over 2 High-Power Fields,
HPFs (x40, with the field diameter of 0.5-0.7 mm in most modern mi-
croscopes), whereas others have evaluated TILs within the area that
extends over to 2 HPFs. Future studies comparing TIL density will en-
hance precision in the issue of surface delineation for TIL density as-
sessment in breast CIS. For the current guidelines, we suggest using the
2 HPFs rule until more evidence offers another approach.
CIS of the breast often spreads throughout the breast, not forming a
solid tumor mass, compared to the invasive cancer. At present, the
significance of TIL heterogeneity in breast CIS and the methods of its
measurement are unclear, therefore we recommend using the average%
of stromal TILs in all areas of CIS that may be encountered on different
slides of the same case.
Intratumoral (or“intraepithelial”) TILs in CIS are much less present
than stromal TILs; furthermore, their assessment is also less
Fig. 3. TILs in DCIS. Pictures showing 4 different
cases (A–D) with varying levels of TILs.
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reproducible on plain H& E sections. Therefore, at present, we do not
recommend the use of intra-tumoral TILs in CIS of the breast and en-
courage further methodological research enabling the more accurate
characterization of this variable.
The existing evidence does not allow formal recommendation for a
clinically relevant breast CIS TIL threshold(s). In order to retain in-
formation and allow the most accurate statistical analyses, we suggest
assessing TILs as a continuous parameter (0–100%). Pathologists should
report their scores in as much detail as they feel comfortable with. Our
current recommendations for TIL evaluation on H& E-stained breast
CIS sections are summarized in Table 3. For general remarks, such as
magnification, slide thickness, cell types to be included, the exclusion of
TILs in and around normal lobules and in areas of necrosis or hyalini-
zation or crush artefacts, we refer to the earlier recommendations on
TIL assessment in invasive breast cancer [7].
3.2.2. Subtyping and functional assessment of TILs
Immunohistochemistry (chromogenic or fluorescent) can give in-
formation on TIL composition and, partially, on their phenotype or/and
functional status. As for TIL assessment on H & E-stained sections, it is
highly recommended to use the full-face sections for IHC analyses.
However, IHC staining of all the sections of a breast CIS lesion can be
costly and the interpretation time consuming.
Tissue microarrays (TMAs) can be helpful in the evaluation of TIL
phenotype by IHC. Studies using TMAs in TIL assessment in breast CIS
are still very rare, so no recommendations for TMA construction aiming
at TIL in situ phenotyping in breast CIS can be made at this point.
Beguinot-Cornillon and colleagues have evaluated TIL im-
munophenotype of 131 breast DCIS using TMAs [40]. TMAs were
constructed by sampling 3 cores of 0.6 mm diameter from each CIS.
Cores were taken from areas with the densest TIL infiltration. In cases of
micro-invasive carcinoma, one cylinder had to contain the micro-in-
vasive component. By this approach TIL composition of richly in-
filtrated pure DCIS significantly differs from the TIL composition of
micro-invasive carcinoma, despite no difference in the level of lym-
phocytic infiltration.
However, using TMAs for phenotyping TIL subpopulations does
have limitations (risk of under-estimation of intra-tumor heterogeneity,
material loss during processing, etc.), but has well known advantages
for screening a high number of cases. In TIL phenotyping, TMAs are
well suited to analyze ratios between TIL subpopulations (T-cells to B-
cells, or CD8+ cells to FOXP3+ cells etc.) as the subpopulations can be
counted on the same surface of the TMA spot. The most important
difficulty lies in determining the area within which TILs will be
counted, as the surface of stromal area is not identical in all TMA spots.
This can be overcome by visual or machine-assisted estimation of the
size of the area in which the counting was done or by use of ocular grids
which highlight the area to evaluate.
Recently developed IHC methods of multiplex staining, which result
in 2–5 color signals on the same slide, allows for co-localization of
different TIL subpopulations also in relation to tumor cells. This ap-
proach might be very useful in the analysis of development of anti- vs
pro-CIS immune-response over time, as these changes may provide
important clues of breast CIS progression [45].
4. Conclusion
Process for biomarker development is long, complex and requires
efforts from the scientific community to proceed through the key steps
of analytic validity, clinical validity and clinical utility [46,47].
TILs in the post-neoadjuvant residual disease setting are gaining
increased importance as stratifying markers in clinical trials, con-
sidering the growing interest on immunotherapeutic strategies after the
1st-line chemotherapy (neoadjuvant). Translational research performed
in post-neoadjuvant treatment trials, for example in TNBC patients with
RD after NACT (NCT02926196, NCT02954874) can help clarifying the
added value of TILs in this setting, as summarized in Savas et al. [48].
Three possible scenarios in case of RD after NACT may be outlined: (i)
intermediate to high TILs in RD, (ii) low TILs in RD and (iii) change in
TILs from before to after NACT. The first case represents the ideal
candidate for immune checkpoint monotherapy/combination since it is
conceivable that the presence of TILs reflects existing but partially ex-
hausted anti-tumor immunity, which only needs to be maintained and/
or boosted. In the second scenario, the absence of an anti-tumor im-
mune response would virtually undermine the effect of immunotherapy
alone. The identification of genomic alterations associated with im-
mune escape could enable the investigation of novel targeted agents, to
be potentially associated with immunotherapy. The potential of the
third scenario should be interpreted within the context of the first and
the second scenario.
Similarly, the evaluation of breast CIS richness in TILs may give
insights into the immunogenicity level of the lesion. Globally, lesions
with no or very low TILs may be considered non-immunogenic, whereas
intermediate to high TIL scores indicate the existence of some immune
response to CIS.
In this review, the Working Group proposes recommendations to
assess TILs in both the post-neoadjuvant residual disease and the CIS
setting, acknowledging the limits of each method. In a similar mind
Table 3
Recommendations for assessing tumor-infiltrating lymphocytes (TILs) in breast carcinoma
in situ.
1. TILs can be evaluated for each type of CIS, whether it is ductal or lobular. This
should be specified in the report and in advance. The same methodology applies
to whether it concerns lobular or ductal breast carcinoma in situ.
2. TILs can be evaluated in CIS as part of an invasive cancer or in CIS with no invasive
component. The same methodology applies. TILs should not be evaluated in the
areas of invasive cancer.
3. The final score of TILs in CIS score should not contain the score of TILs in the area
containing invasive cells.
4. Evaluation of all sections containing CIS of one patient is recommended. Full-face
sections (4–5 μm) are preferred over biopsies whenever possible. Cores or
vacuum-assisted biopsies can be used in the neoadjuvant setting. No validated
methodology has been developed to score TILs in CIS after neoadjuvant
treatment.
5. These recommendations are for evaluation of TILs on hematoxylin & eosin-stained
sections of formalin-fixed/paraffin-embedded tissues.
6. Only stromal TILs should be reported. TILs located within CIS-lesions (between the
in situ tumor cells), i.e. intra-epithelial tumoral TILs, should not be assessed.
•We recommend defining the stromal compartment as the area of the specialized
stroma surrounding the CIS-lesions (the “periductal” area). If a DCIS is
surrounded by a fibrous rim with TIL immediately adjacent to it, these should be
assessed as well. If this area of specialized stroma is not readily distinguishable,
one can use a more arbitrary stromal area which extends over 2 HPF (x40).
•Any type of circumferential TIL infiltration should be taken into account
(minimal, partial, subtotal or total).
•If many CIS lesions are encountered, TIL evaluation in all lesions should be done
and the mean value should be derived. Do not focus on hot spots.
•TILs that are in continuity between the invasive lesions and the in situ lesions,
without clear distinction whether they are associated to the invasive or to the in
situ lesion, should be assessed within the 2HPF area for DCIS-TILs while the
remaining TILs are part of the invasive component.
•No distinction to be made between TILs surrounding CIS lesions of different
differentiation grades.
7. TILs around normal lobules, wherever they are found, should not be assessed.
8. TILs in tumor zones with crush artefacts, necrosis, regressive hyalinization as well
as in the previous core biopsy site should not be assessed.
9. The result of TIL assessment should be reported as% of stromal area surface
occupied by TILs. The authors recommend to report the result as a continuous
parameter (0–100%). TIL evaluators should report their results in as much detail
they feel comfortable with. In determining the percentage of stromal area surface
occupied by TILs, the dissociated growth pattern of lymphocytes needs to be
taken into account. Lymphocytes typically do not form solid cellular aggregates,
therefore the designation “100% stromal TILs” would still allow some empty
tissue space between the individual lymphocytes.
10. No formal recommendation for a clinically relevant TIL threshold(s) can be given
at this stage. From our point of view, a valid methodology is currently more
important than issues of thresholds for clinical use, which will be determined
once a solid methodology is in place.
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frame, TILs should be considered as just one piece of the immunogenic
puzzle of the tumor and thus their assessment complementary to other
approaches in clinical research. More clinical studies will determine to
what extent TILs solely or combined with other morphological (for
example, subtyping) or genomics-based variables (for example, gene
expression profiles) will prove to be sufficiently robust, in terms of
clinical utility, to be implemented in a daily practice setting. As an
example, the Working Group has activated an international effort to
include TILs in the RCB index in order to gain a more precise risk
stratification in breast cancer after NACT.
These recommendations represent a consensus guidance for pa-
thologists, aimed to achieve the highest possible consistency between
studies. For this, a comparison of data from different studies is needed,
using a similar methodology. Conceptually, the basics presented here
may also be applied to other tumor types such as, for example, post-
neoadjuvant ovarian, esophagus, head-and-neck and rectal cancer.
Future updates on the proposed methodologies will be performed as
more evidence becomes available and the field progresses.
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